Celsis In Vitro Technologies is the premier supplier of high-quality hepatocytes, microsomes, s9, stellate and kupfner cells, cytosol and other custom cellular and sub-cellular products used to speed up ADME-Tox in vitro research for drug discovery and development. Celsis IVT, a division of Celsis International, holds a patent on the process of targeted, purpose-pooling of human hepatocytes for its unique LiverPool cryopreserved product.
